CC
ALDX icon

Caxton Corporation’s Aldeyra Therapeutics ALDX Stock Holding History

Caxton Corporation’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,784
Closed -$134K – 56
2021
Q2 		$134K Sell
11,784
-17,768
-60% -$214K 0.09% 53
2021
Q1 		$351K Buy
+29,552
New +$340K 0.23% 48

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

Caxton Corporation's ALDX Position: Q3 2021 in Review

Caxton Corporation sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 11,784 shares — an estimated $134K sold.

Caxton Corporation first reported a position in ALDX in Q1 2021 and held it in 2 quarters. The position peaked at $351K in Q1 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

  • Caxton Corporation reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Caxton Corporation sold 11,784 Aldeyra Therapeutics shares in Q3 2021, an estimated $134K.
  • Caxton Corporation first reported a position in Aldeyra Therapeutics in Q1 2021 and held it in 2 quarters.
  • Caxton Corporation's Aldeyra Therapeutics position peaked at $351K in Q1 2021.
  • 117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on Caxton Corporation's 13F filing for Q3 2021, filed 15 Nov 2021.